» Articles » PMID: 23062364

Activation of the Two MicroRNA Clusters C19MC and MiR-371-3 Does Not Play Prominent Role in Thyroid Cancer

Overview
Journal Mol Cytogenet
Publisher Biomed Central
Specialty Biochemistry
Date 2012 Oct 16
PMID 23062364
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Chromosomal rearrangements of band 19q13.4 are frequent cytogenetic alterations in benign thyroid adenomas. Apparently, these alterations lead to the upregulation of genes encoding microRNAs of two clusters mapping to the breakpoint region, i.e. miR-371-3 and C19MC. Since members of both clusters have been associated with neoplastic growth in other tumor entities the question arises whether or not their upregulation predisposes to malignant transformation of follicular cells of the thyroid. To address this question we have quantified the expression of miR-372 and miR-520c-3p in samples of 114 thyroid cancers including eight anaplastic thyroid carcinomas, 25 follicular thyroid carcinomas, 78 papillary thyroid carcinomas (including 13 follicular variants thereof), two medullary thyroid carcinomas and one oncocytic thyroid carcinoma. Additionally, we quantified miR-371a-3p and miR-519a-3p in selected samples. While in neither of the cases miR-520c-3p and miR-519a-3p were found to be upregulated, one papillary and one anaplastic thyroid carcinoma, respectively, showed upregulation of miR-372 and miR-371a-3p. However, in these cases fluorescence in situ hybridization did not reveal rearrangements of the common breakpoint region as affected in adenomas. Thus, these rearrangements do apparently not play a major role as first steps in malignant transformation of the thyroid epithelium. Moreover, there is no evidence that 19q13.4 rearrangements characterize a subgroup of thyroid adenomas associated with a higher risk to undergo malignant transformation. Vice versa, the mechanisms by which 19q13.4 rearrangements contribute to benign tumorigenesis in the thyroid remain to be elucidated.

Citing Articles

Identification of microRNA signature in the progression of gestational trophoblastic disease.

Zhao J, Cheng W, Wang Y, Cai M, Wu W, Zhang H Cell Death Dis. 2018; 9(2):94.

PMID: 29367697 PMC: 5833456. DOI: 10.1038/s41419-017-0108-2.


Inhibition of Gastric Tumor Cell Growth Using Seed-targeting LNA as Specific, Long-lasting MicroRNA Inhibitors.

Staedel C, Varon C, Nguyen P, Vialet B, Chambonnier L, Rousseau B Mol Ther Nucleic Acids. 2015; 4:e246.

PMID: 26151747 PMC: 4561653. DOI: 10.1038/mtna.2015.18.

References
1.
Liang Y, Ridzon D, Wong L, Chen C . Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007; 8:166. PMC: 1904203. DOI: 10.1186/1471-2164-8-166. View

2.
Belge G, Rippe V, Meiboom M, Drieschner N, Garcia E, Bullerdiek J . Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations. Cytogenet Cell Genet. 2001; 93(1-2):48-51. DOI: 10.1159/000056947. View

3.
Cao H, Yang C, Rana T . Evolutionary emergence of microRNAs in human embryonic stem cells. PLoS One. 2008; 3(7):e2820. PMC: 2474702. DOI: 10.1371/journal.pone.0002820. View

4.
Kroll T, Sarraf P, Pecciarini L, Chen C, Mueller E, Spiegelman B . PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483):1357-60. DOI: 10.1126/science.289.5483.1357. View

5.
Morin R, OConnor M, Griffith M, Kuchenbauer F, Delaney A, Prabhu A . Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008; 18(4):610-21. PMC: 2279248. DOI: 10.1101/gr.7179508. View